Bibliographic citations
Aliaga, R., Medina, B. (2025). Farmacovigilancia en pacientes con diabetes mellitus tipo ii atendidos en el Hospital Sub Regional de Andahuaylas - enero - agosto 2023 [Universidad María Auxiliadora]. https://hdl.handle.net/20.500.12970/2515
Aliaga, R., Medina, B. Farmacovigilancia en pacientes con diabetes mellitus tipo ii atendidos en el Hospital Sub Regional de Andahuaylas - enero - agosto 2023 []. PE: Universidad María Auxiliadora; 2025. https://hdl.handle.net/20.500.12970/2515
@misc{renati/2052358,
title = "Farmacovigilancia en pacientes con diabetes mellitus tipo ii atendidos en el Hospital Sub Regional de Andahuaylas - enero - agosto 2023",
author = "Medina Rincon, Bleker",
publisher = "Universidad María Auxiliadora",
year = "2025"
}
To identify pharmacovigilance, a quantitative, descriptive methodology was used, with a non-experimental and cross- sectional design, the population was 420 notifications of suspected ADRs and the sample was 201 cases, documentary analysis was the technique used, together with a data sheet as an instrument. The results indicate a high rate in women, 48.3% of ADRs were not classified, according to the causality algorithm, 45.9% unlikely. ATC classification 46.8% of the adverse reactions correspond to reactions to dermatological drugs, the severity of the ADR was predominantly mild with 91.0%, with 6.5% classified as moderate and 2.5% as severe, it was concluded that there is a high proportion of unclassified or improbable ADRs, with a predominance of reactions to dermatological drugs and a majority mild in patients with type II diabetes mellitus.
This item is licensed under a Creative Commons License